Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

Effects of Pregnane X Receptor (PXR) Activation on Human Glucose, Lipid and Hormone Homeostasis

Phase 4

Completed

Conditions: Glucose Metabolism

Interventions: Drug: Rifampicin

First Posted Date: 2011-02-10

Last Posted Date: 2012-09-10

Lead Sponsor: University of Oulu

Target Recruit Count: 12

Registration Number: NCT01293422

Locations: 🇫🇮
Oulu University Hospital, Oulu, Finland

Study of Rifampicin in Multiple System Atrophy

Phase 3

Terminated

Conditions: Multiple System Atrophy

Interventions: Drug: Rifampicin
Drug: placebo

First Posted Date: 2011-02-01

Last Posted Date: 2014-03-28

Lead Sponsor: Phillip Low

Target Recruit Count: 100

Registration Number: NCT01287221

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 6 locations

Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan

Phase 1

Withdrawn

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Sitaxsentan alone
Drug: Sitaxsentan
Drug: Rifampin

First Posted Date: 2010-12-02

Last Posted Date: 2015-03-05

Lead Sponsor: Pfizer

Registration Number: NCT01251835

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: GSK1349572
Drug: Rifampin
Drug: Rifabutin

First Posted Date: 2010-11-01

Last Posted Date: 2017-06-08

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 27

Registration Number: NCT01231542

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB

Phase 2

Completed

Conditions: Tuberculosis, Pulmonary

Interventions: Drug: SQ109
Drug: Rifampicin

First Posted Date: 2010-10-11

Last Posted Date: 2013-01-14

Lead Sponsor: Michael Hoelscher

Target Recruit Count: 90

Registration Number: NCT01218217

Locations: 🇿🇦
TASK Applied Sciences, Cape Town, South Africa
🇿🇦
University of Cape Town, Cape Town, South Africa

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Adult Solid Neoplasm

Interventions: Drug: Gamma-Secretase Inhibitor RO4929097
Drug: Ketoconazole
Drug: Rifampin
Drug: Midazolam Hydrochloride
Drug: Omeprazole
Drug: Tolbutamide
Drug: Dextromethorphan Hydrobromide
Other: Pharmacological Study
Other: Laboratory Biomarker Analysis

First Posted Date: 2010-10-11

Last Posted Date: 2014-12-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT01218620

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: crizotinib
Drug: rifampin

First Posted Date: 2010-06-22

Last Posted Date: 2011-10-24

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT01147055

Locations: 🇺🇸
Pfizer Investigational Site, South Miami, Florida, United States

A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax

Phase 1

Completed

Conditions: Lymphoma, Including Chronic Lymphocytic Leukemia
Solid Tumors

Interventions: Drug: navitoclax
Drug: Rifampin

First Posted Date: 2010-05-12

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 12

Registration Number: NCT01121133

Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

Phase 1

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Dapagliflozin
Drug: Rifampin

First Posted Date: 2010-02-15

Last Posted Date: 2016-10-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 14

Registration Number: NCT01068756

Locations: 🇺🇸
Ppd Development, Austin, Texas, United States

High Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis

Phase 2

Completed

Conditions: Smear Positive, Pan-sensitive, Pulmonary Tuberculosis

Interventions: Drug: Rifapentine
Drug: Rifampin

First Posted Date: 2010-01-07

Last Posted Date: 2012-08-17

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 60

Registration Number: NCT01043575

Locations: 🇺🇬
Uganda / Case Western Reserve Research Collaboration, Kampala, Uganda
🇺🇸
Audie L. Murphy VA Medical Center, San Antonio, Texas, United States
🇺🇸
Denver Public Health, Denver, Colorado, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy